Loading, Please Wait...
MOUNTAIN VIEW, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that its patented MicroPulse® technology played a pivotal role in research presented at the 2019 Association for Research in Vision & Ophthalmology (ARVO) and American Society of Cataract & Refractive Surgeons (ASCRS) meetings, to be held in Vancouver, British Columbia, and San Diego, CA, respectively.
At these annual meetings, there will be 20 scientific presentations on MicroPulse laser therapy that utilize IRIDEX’s Cyclo G6® Glaucoma Laser and MicroPulse P3® Delivery Device for treating multiple types of glaucoma, and IRIDEX’s IQ family of laser consoles for treating a variety of retinal disorders. This scientific data, and data presented at the American Glaucoma Society and World Glaucoma Congress meetings earlier in 2019, brings the total of IRIDEX-related data sets to approximately 40, demonstrating an increase in available, efficacious data for MicroPulse technology.
"There is considerable clinical value in non-invasive procedures that lower intraocular pressure without placing activity restriction on the patient postoperatively," commented Jella An, MD, Director of Glaucoma Service, University of Missouri. "With its strong safety and efficacy profile, MicroPulse transscleral cyclophotocoagulation (MP-TSCPC) offers glaucoma specialists compelling options for treating patients who don't respond to medication alone,” commented Dr. An. “I am looking forward to sharing how the research I have conducted alongside fellow glaucoma specialists continues to validate MP-TSCPC in clinical practice.”
“As one of the most influential pioneers in ophthalmic laser therapy, we are thrilled to see our MicroPulse technology continue our legacy of innovation and quality in the market,” said William Moore, Chief Executive Officer of IRIDEX. “MicroPulse technology gives physicians the control and results they need when managing some of their patients’ most serious glaucoma and retinal conditions. We’re honored to be included in important research driving the future of glaucoma and retina care.”
At the ARVO and ASCRS meetings, there are several opportunities for attendees to join physician presentations and IRIDEX-sponsored events to learn how to incorporate MicroPulse laser therapy into clinical practice using our Cyclo G6 Glaucoma Laser and MicroPulse P3 Delivery Device.
Noteworthy Data Presented at ARVO
Several studies presented at ARVO demonstrate the short- and long-term safety and efficacy of MicroPulse laser treatment for multiple types of glaucoma, including open-angle glaucoma and neovascular glaucoma, and for retinal conditions. These studies, while focusing on a wide range of clinical topics, further validate MicroPulse laser therapy as a safe, effective, and versatile treatment option for multiple serious ophthalmic conditions.
Key presentations include:
: Efficacy of MicroPulse Laser Trabeculoplasty in Open Angle Glaucoma
Clemente A, et.al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall
Post-operative one-hour intraocular pressure spikes and long term pressure efficacy in micropulse laser trabeculoplasty (MLT) vs selective laser trabeculoplasty (SLT)
Giovingo M, et. al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall
Efficacy and safety of transscleral micropulsed laser in the treatment of glaucoma refractory to treatment
Delgadillo L, et. al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall
Short-term outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Korean patients
Chung J. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall
MicroPulse Transscleral Cyclophotocoagulation in Refractory Glaucoma. 6 month follow-up
Del Hierro C., et. al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall
: Outcomes of MicroPulse Cyclophotocoagulation in Adult Glaucoma Patients
Grisham E., et. al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall
The Efficacy and Safety of MicroPulse Photocyclophotocoagulation in the Treatment of Refractory Advanced Pediatric Glaucomas
Reiser J B. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall
: Three-Year Retrospective Study of Treatment with Micropulse Cyclophotocoagulation as a Primary Procedure for Neovascular Glaucoma
Giovingo M, et. al. Sunday, April 28, 2019 | 1:00 PM – 2:45 PM | West Exhibition Hall
Intraocular pressure reduction profile in patients with refractory glaucoma submitted to micropulse transscleral cyclophotocoagulation
Dorairaj S, et. al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall
: Pars plicata versus pars plana application of micropulse transscleral cyclophotocoagulation
Waibel A. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall
Presentation Number 2825
: Microscope Real-time Video, High- resolution OCT & Histopathology to Assess How Transcleral Micropulse Laser Affects the Sclera, Ciliary Body, Muscle, Secretory Epithelium, Suprachoroidal Space & Aqueous Outflow System
Johnstone M. Tuesday, April 30, 2019 | 9:15 – 9:30 AM | West 212-214
Presentation Number 2826
: Clinical outcomes of micropulse transscleral cyclophotocoagulation in post-keratoplasty patients
Kang J. Tuesday, April 30, 2019 | 9:30 – 9:45 AM | West 212-214
Outcomes of Micropulse Transscleral Cyclophotocoagulation in a Hispanic Population
Vincent L., et. Al. Tuesday, April 30, 2019 | 11:45 – 1:30 PM | West Exhibition Hall
MicroPulse Laser Therapy for Retina
Comparing intravitreal bevacizumab, sub threshold macular laser (STML) and intravitreal dexamethasone implant (0.7mg) in the initial treatment of diabetic macular edema (DME) in a resident led clinic
Mughal M., et. al. Tuesday, April 30, 2019 | 11:45 – 1:30 PM | West Exhibition Hall
Subthreshold laser treatment following full thickness macular hole surgery
Stanzel B. Thursday, May 2, 2019 | 3:00 – 4:45 PM | West Exhibition Hall
Presentation Number 3861:
Subthreshold MicroPulse Laser Treatment of Human Diabetic Macular Edema: The Role of Müller Cells, Retinal Pigment Epithelium and the Inflammatory Cascade
Midena E. Tuesday, April 30, 2019 | 3:00 – 3:15 PM | East Ballroom B
Noteworthy Data Presented at ASCRS
Outcomes of MicroPulse Transscleral Cyclophotocoagulation in Keratoplasty Eyes
Feng M., Price M., Price W. Sunday, May 05, 2019 | 04:02 PM - 04:07 PM |SDCC - Upper Level, Room 7A
A study by Matthew Feng et. al., evaluates outcomes of MicroPulse transscleral cyclophotocoagulation for intraocular pressure control in keratoplasty eyes, finding that MicroPulse laser treatment was a non-invasive alternative to glaucoma filtration surgery for IOP reduction in keratoplasty eyes. Note: This study was published in March in the journal Cornea 2019;38:542–545.
IRIDEX Events at ASCRS
Eye care professionals interested in learning about IRIDEX MicroPulse technology are encouraged to attend IRIDEX events being held at the 2019 ASCRS congress, including:
MicroPulse TSCPC as Treatment for Failed MIGS Procedures
Sunday, May 5 (7:15 – 8:30 AM) at the Marriot Marquis Marina
In this educational breakfast, learn how innovative clinicians Jella An, MD (MU Health Care) and Ahad Mahootchi, MD (The Eye Clinic of Florida) are using the IRIDEX Cyclo G6 laser to treat uncontrolled glaucoma patients. Discover their specific cases, patient selection, clinical evidence, and outcomes. Register at iridex.com/ascrs or email@example.com
MicroPulse TSCPC: Meet the Experts
Throughout the conference at IRIDEX Booth #3129
Throughout the 2019 ASCRS conference, IRIDEX will host a series of expert lectures on the Cyclo G6 laser’s use in clinical practice. Experienced ophthalmologists, including Michael Giovingo, MD (Cook County Health & Hospital), Shan Lin, MD (Glaucoma Center of San Francisco) and Ian P. Conner, MD PhD (UPMC) share their clinical case studies and insights in casual one-on-one conversations with audience participants.
See the full list of attendees and register at iridex.com/ascrs or firstname.lastname@example.org
IRIDEX is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit http://www.iridex.com.
Investor Relations Contact:
Pascale Communications, LLC.